Aardvark Therapeutics(AARD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AARD Aardvark Therapeutics

已收盘 07-15 16:00:00 EDT

6.67

+0.41

+6.55%

盘后6.67

+0.000.00%

19:51 EDT

最高6.72	最低6.02	成交量18.65万
今开6.24	昨收6.26	日振幅11.14%
总市值1.45亿	流通市值7,449万	总股本2,170万
成交额120.71万	换手率1.67%	流通股本1,117万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":6.67,"timestamp":1784145600000,"preClose":6.26,"halted":0,"volume":186500,"hourTrading":{"tag":"盘后","latestPrice":6.67,"preClose":6.67,"latestTime":"19:51 EDT","volume":242,"amount":1611.788,"timestamp":1784159494879,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.06549520766773165,"floatShares":11168300,"shares":21696893,"eps":-3.207951,"marketStatus":"已收盘","change":0.41,"latestTime":"07-15 16:00:00 EDT","open":6.24,"high":6.72,"low":6.0225,"amount":1207074.625,"amplitude":0.111422,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.207951,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1784188800000},"marketStatusCode":5,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":6.26,"preHourTrading":{"tag":"盘前","latestPrice":6.39,"preClose":6.26,"latestTime":"09:29 EDT","volume":1107,"amount":7068.080204100001,"timestamp":1784122141042,"change":0.13,"changeRate":0.020767,"amplitude":0.08147},"postHourTrading":{"tag":"盘后","latestPrice":6.67,"preClose":6.67,"latestTime":"19:51 EDT","volume":242,"amount":1611.788,"timestamp":1784159494879,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.162408,"impliedVol":1.9659,"impliedVolPercentile":0.8},"requestUrl":"/m/hq/s/AARD/tweets","defaultTab":"tweets","newsList":[{"id":"1189600944","title":"Aardvark Therapeutics将揭盲Ard-101的HERO与OLE试验数据以进行评估，并确定该项目的后续计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1189600944","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189600944?lang=zh_cn&edition=full","pubTime":"2026-05-15 04:03","pubTimestamp":1778789004,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc宣布，公司将揭盲其候选药物Ard-101在HERO试验和开放标签扩展（OLE）试验中的数据，以进行全面评估。此举旨在基于这些关键临床数据，为Ard-101项目的未来发展路径做出决策。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157105953","title":"Aardvark Therapeutics 计划揭盲HERO与OLE研究数据，为FDA临床搁置后的前行之路提供指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1157105953","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157105953?lang=zh_cn&edition=full","pubTime":"2026-05-15 04:03","pubTimestamp":1778788980,"startTime":"0","endTime":"0","summary":"在遭遇美国食品药品监督管理局（FDA）的临床搁置后，Aardvark Therapeutics 正计划揭盲其关键研究HERO与开放标签扩展（OLE）试验的数据。此举旨在深入分析现有数据，为确定公司未来的临床开发路径提供关键依据。通过审视这些未公开的详细结果，公司期望能更好地理解监管机构的关切，并据此制定出清晰、可行的后续策略，以推动其研发项目继续向前迈进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132251302","title":"Aardvark Therapeutics与Piper Sandler签订股权分销协议，于2026年3月23日提交SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1132251302","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132251302?lang=zh_cn&edition=full","pubTime":"2026-03-24 18:11","pubTimestamp":1774347083,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. 已与Piper Sandler公司正式签署了一项股权分销协议。该协议的具体条款于2026年3月23日通过美国证券交易委员会（SEC）的文件对外公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146815608","title":"Aardvark Therapeutics暂停针对PWS的Ard-101三期HERO及OLE试验；最新指引预计2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1146815608","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146815608?lang=zh_cn&edition=full","pubTime":"2026-03-24 04:23","pubTimestamp":1774297410,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics公司宣布，已暂停其候选药物Ard-101用于治疗普瑞德-威利综合征（PWS）的三期HERO临床试验及开放标签扩展（OLE）研究。\n公司表示，预计将在2026年第二季度提供关于该研发项目下一步计划的进一步指导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125745058","title":"Aardvark Therapeutics暂停Ard-201肥胖症项目，包括力量与体能试验；进一步指引预计2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1125745058","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125745058?lang=zh_cn&edition=full","pubTime":"2026-03-24 04:21","pubTimestamp":1774297278,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics已决定暂停其Ard-201肥胖症治疗项目的研发进程，该项目原计划包含针对患者力量与体能改善的临床试验。公司表示，关于该项目的后续发展方向及详细计划，预计将在2026年第二季度提供进一步的明确指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103365650","title":"RBC下调Aardvark Therapeutics评级至行业平配，目标价大幅砍至6美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103365650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103365650?lang=zh_cn&edition=full","pubTime":"2026-03-02 13:52","pubTimestamp":1772430778,"startTime":"0","endTime":"0","summary":"加拿大皇家银行（RBC）宣布，将Aardvark Therapeutics的股票评级从“跑赢大盘”下调至“行业平配”，同时将其目标价从18美元大幅削减至6美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162306225","title":"Aardvark Therapeutics：因超出目标剂量出现可逆性心脏观察结果，暂停Hero及开放标签扩展试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1162306225","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162306225?lang=zh_cn&edition=full","pubTime":"2026-02-28 05:08","pubTimestamp":1772226491,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics宣布，在发现高于目标剂量出现可逆性心脏相关观察结果后，已决定暂停其Hero试验以及开放标签扩展研究。公司强调，该心脏异常现象在停药后具有可逆性，目前正与监管机构密切沟通，进一步评估相关数据以确定后续研究方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177858931","title":"Aardvark Therapeutics：基于超目标治疗剂量下可逆心脏观察结果作出决策","url":"https://stock-news.laohu8.com/highlight/detail?id=1177858931","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177858931?lang=zh_cn&edition=full","pubTime":"2026-02-28 05:08","pubTimestamp":1772226490,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics公司宣布，其决策依据是在高于目标治疗剂量下发现的可逆性心脏观察结果。这一发现对药物安全性评估具有关键意义，表明在特定剂量范围内出现的心脏影响是可逆的，为公司后续临床开发路径提供了重要参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174773215","title":"Aardvark Therapeutics 成立美国子公司 推进皮肤病产品管线发展；任命 Bryan Jones 为首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1174773215","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174773215?lang=zh_cn&edition=full","pubTime":"2026-02-12 21:06","pubTimestamp":1770901613,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics 宣布成立新的美国子公司，旨在支持其皮肤病产品管线的开发进程。公司同时宣布，任命 Bryan Jones 担任该子公司的首席执行官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193243066","title":"Aardvark Therapeutics宣布向FDA提交并获IRB批准其主打候选药物ARD-101的修订试验方案，扩大普瑞德-威利综合征III期研究受试者资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1193243066","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193243066?lang=zh_cn&edition=full","pubTime":"2026-02-10 21:05","pubTimestamp":1770728724,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics今日宣布，已向美国食品药品监督管理局（FDA）提交了其主打候选药物ARD-101的修订临床试验方案，并已获得机构审查委员会（IRB）的批准。此项修订旨在扩大针对普瑞德-威利综合征（PWS）的III期临床研究的受试者资格范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518226139","title":"Aardvark Therapeutics(AARD.US)获B of A Securities首次覆盖，给予买入评级, 目标价22.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518226139","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518226139?lang=zh_cn&edition=full","pubTime":"2025-03-10 20:41","pubTimestamp":1741610495,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics(AARD.US)获B of A Securities首次覆盖，给予买入评级, 目标价22.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/10204148634837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AARD","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://aardvarktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1507},{"period":"1month","weight":0.6051},{"period":"3month","weight":0.2323},{"period":"6month","weight":-0.5922},{"period":"1year","weight":-0.4831},{"period":"ytd","weight":-0.523}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0741},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.2033},{"period":"ytd","weight":0.1025}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aardvark Therapeutics, Inc.于2017年5月17日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，专注于开发新颖的小分子疗法，以激活用于治疗代谢疾病的先天稳态途径。该公司瞄准了与缓解饥饿相关的生物途径，该公司认为这些途径有可能为患者带来变革性的结果。该公司已将精力集中在开发选择性化合物上，针对与饥饿相关的情况开发苦味受体。","exchange":"NASDAQ","name":"Aardvark Therapeutics","nameEN":"Aardvark Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aardvark Therapeutics(AARD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aardvark Therapeutics(AARD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aardvark Therapeutics,AARD,Aardvark Therapeutics股票,Aardvark Therapeutics股票老虎,Aardvark Therapeutics股票老虎国际,Aardvark Therapeutics行情,Aardvark Therapeutics股票行情,Aardvark Therapeutics股价,Aardvark Therapeutics股市,Aardvark Therapeutics股票价格,Aardvark Therapeutics股票交易,Aardvark Therapeutics股票购买,Aardvark Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aardvark Therapeutics(AARD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aardvark Therapeutics(AARD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}